drugset / Trial / NCT01948895

Desvenlafaxine Monotherapy in Dysthymia

NCT01948895

NaSingle-groupOpen-labelTreatment

Summary

This multi-centred study will be conducted at two centres. The design will be an open label, flexible-dose study. This investigation will evaluate the efficacy of Desvenlafaxine monotherapy for patients who meet diagnostic criteria for dysthymia.

Timeline

Start
2012-08
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 50 mg
Subject Desvenlafaxine Other / unclassified 100 mg

Indications